John Parkinson

The Centers for Disease Control and Prevention (CDC) and the National Foundation for Infectious Diseases (NFID) both weigh in on the evolving summer COVID-19 season, and strategies for prevention.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

The company, Al-Safa US, is recalling approximately 2010 pounds of imported frozen ready-to-eat chicken products.

As of July 2nd, 2024, 449 people have been sickened and 124 people hospitalized.

The report comes from Colorado, and public health officials have not yet identified the source of transmission.

The $176 million award is for late-stage development of widespread immunization capability against H5 (avian) influenza, should such vaccines be needed.

The case occurred to a man in Colorado who had direct contact with cattle and state public health officials offer details on the patient as well as the risk to the public.

The Johnson & Johnson therapy, bedaquiline (Sirturo), was given the nod in both the United States and Europe for mycobacterium tuberculosis resistant to at least rifampicin and isoniazid.

A new study shows a greater likelihood of contracting this foodborne illness associated with a local area's socioeconomic vulnerability index (SVI) rank level, and reinforces the importance of addressing disparities in food safety.

Biopharmaceutical company, Dynavax, is comparing its investigational immunization against a FDA-approved vaccine.

The federal agency says everyone 75 years of age and older should receive the RSV vaccine.

A retracted paper that erroneously claimed the measles, mumps and rubella (MMR) vaccine caused autism has repercussions still being felt today around topics such as vaccination, misinformation and disinformation, and measles incidence rates.

The WHO reports the variant, clade I MPXV, has been circulating in a region within the Democratic Republic of Congo since last year.

Those individuals who received older versions of vaccines did not see significantly reduced risks of severe COVID-19 outcomes.

In a small study, recurrent Clostridioides difficile infection (CDI) therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.

Berkeley Heights, NJ-based biopharmaceutical company, CorMedix, is working towards an expanded indication for its DefenCath product, for the prevention of these healthcare-associated infections.

With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.

The state's attorney general filed the lawsuit against Pfizer for its ‘misleading statements’ about the vaccine.

New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.

A study points to inpatients who were 50 years and older with the respiratory illness suffering from heart-related complications with the largest number of them having acute heart failure. 

Seres is selling their microbiota product to Nestlé and expects to make a smooth transition as they already have an existing partnership.

The company announced data this morning for its investigational mRNA-1083 vaccine and plans to continue collecting data and working towards submitting a Biological License Application (BLA) for it.

The federal agency’s decision expands the vaccine’s eligibility to people 50 years of age and older, making it the first one for this age group.

FDA VRBPAC recommends protection against JN1 for the fall COVID-19 vaccines, a multidrug-resistant form of gonorrhea gives cause for concern, piperacillin-tazobactam shown to have higher mortality than cefepime for sepsis, and more this week from Contagion.

Although there is a rise in the FLiRT family of mutations, the committee decided to seek protection against the older strain.

Atea pharmaceuticals is presenting data at a European liver conference this week showing a high efficacy for its combination therapy at 12 weeks post-treatment.

A continued clarion call is being sounded about the drug-resistant pathogen.

The organization included numerous bacterium that are seen as critical threats to patients.

The clearance rate varied across states, but were not close to the 2025 or 2030 goals across all jurisdictions.

The company’s mRNA 1345 vaccine was given the nod by the federal agency and is indicated for seniors for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD).